AnaptysBio, Inc (ANAB) stock
ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026Market cap $2.28BP/E –Yield –
AnaptysBio shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
AnaptysBio's shares outstanding was 46M at Jun 30, 2026. For fiscal 2025 it was 30M, up 2.3% from the year before. Over ten years it grew 28.0% a year on average. The highest annual figure on record is 30M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 30M | +2.3% |
| FY2024 | Dec 31, 2024 | 30M | +9.7% |
| FY2023 | Dec 31, 2023 | 27M | -4.4% |
| FY2022 | Dec 31, 2022 | 28M | +2.7% |
| FY2021 | Dec 31, 2021 | 27M | +0.5% |
| FY2020 | Dec 31, 2020 | 27M | +0.9% |
| FY2019 | Dec 31, 2019 | 27M | +9.7% |
| FY2018 | Dec 31, 2018 | 25M | +24.7% |
| FY2017 | Dec 31, 2017 | 20M | +650.2% |
| FY2016 | Dec 31, 2016 | 3M | +3.4% |
| FY2015 | Dec 31, 2015 | 3M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 46M | +60.6% |
| Q1 FY2026 | Mar 31, 2026 | 29M | -6.4% |
| Q4 FY2025 | Dec 31, 2025 | 34M | -4.1% |
| Q3 FY2025 | Sep 30, 2025 | 29M | +0.4% |
| Q2 FY2025 | Jun 30, 2025 | 29M | +5.3% |
| Q1 FY2025 | Mar 31, 2025 | 31M | +14.3% |
| Q4 FY2024 | Dec 31, 2024 | 35M | +32.1% |
| Q3 FY2024 | Sep 30, 2024 | 29M | +8.8% |
| Q2 FY2024 | Jun 30, 2024 | 27M | +2.7% |
| Q1 FY2024 | Mar 31, 2024 | 27M | -4.1% |
| Q4 FY2023 | Dec 31, 2023 | 27M | -6.6% |
| Q3 FY2023 | Sep 30, 2023 | 27M | -6.2% |
| Q2 FY2023 | Jun 30, 2023 | 27M | -5.6% |
| Q1 FY2023 | Mar 31, 2023 | 28M | +0.9% |
| Q4 FY2022 | Dec 31, 2022 | 28M | +3.3% |
| Q3 FY2022 | Sep 30, 2022 | 28M | +3.1% |
| Q2 FY2022 | Jun 30, 2022 | 28M | +3.0% |
| Q1 FY2022 | Mar 31, 2022 | 28M | +1.3% |
| Q4 FY2021 | Dec 31, 2021 | 28M | +0.7% |
| Q3 FY2021 | Sep 30, 2021 | 27M | +0.4% |
| Q2 FY2021 | Jun 30, 2021 | 27M | +0.4% |
| Q1 FY2021 | Mar 31, 2021 | 27M | +0.4% |
| Q4 FY2020 | Dec 31, 2020 | 27M | +0.7% |
| Q3 FY2020 | Sep 30, 2020 | 27M | +1.0% |
| Q2 FY2020 | Jun 30, 2020 | 27M | +0.9% |
| Q1 FY2020 | Mar 31, 2020 | 27M | +1.0% |
| Q4 FY2019 | Dec 31, 2019 | 27M | +1.3% |
| Q3 FY2019 | Sep 30, 2019 | 27M | +12.1% |
| Q2 FY2019 | Jun 30, 2019 | 27M | +12.9% |
| Q1 FY2019 | Mar 31, 2019 | 27M | +13.4% |
| Q4 FY2018 | Dec 31, 2018 | 27M | +15.9% |
| Q3 FY2018 | Sep 30, 2018 | 24M | +18.5% |
| Q2 FY2018 | Jun 30, 2018 | 24M | +18.1% |
| Q1 FY2018 | Mar 31, 2018 | 24M | +55.6% |
| Q4 FY2017 | Dec 31, 2017 | 23M | +772.9% |
| Q3 FY2017 | Sep 30, 2017 | 20M | +673.2% |
| Q2 FY2017 | Jun 30, 2017 | 20M | – |
| Q1 FY2017 | Mar 31, 2017 | 15M | – |
| Q4 FY2016 | Dec 31, 2016 | 3M | – |
| Q3 FY2016 | Sep 30, 2016 | 3M | – |
See a number that looks wrong?